Node Not Found: gynecologic cancer Solid Tumors - The ASCO Post

Your search for solid tumors matches 291 pages

Showing 1 - 50


solid tumors

AKT Inhibitor Activity in AKT1-Mutant Solid Tumors

As reported by Hyman et al in the Journal of Clinical Oncology, a basket study has shown activity of an investigational ATP-competitive pan-AKT kinase inhibitor (AZD5363) in solid tumors with AKT1 E17K mutation. Study Details In the study, 52 patients with advanced estrogen...

colorectal cancer
solid tumors

FDA Grants Accelerated Approval to Pembrolizumab for First Tissue/Site Agnostic Indication

On May 23, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for adult and pediatric patients with unresectable or metastatic, microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed ...

solid tumors

First-in-Class T-Cell Stimulator Varlilumab in Advanced Solid Tumors

A phase I study reported by Burris et al in the Journal of Clinical Oncology has shown that the first-in-class agonist anti-CD27 antibody varlilumab is well tolerated and active in patients with advanced solid tumors. CD27 is a co-stimulatory molecule on T cells that induces intracellular signaling ...

solid tumors

Estimates of Cancer Population Reference Values for PROMIS Patient-Reported Outcome Domains

  As reported in the Journal of Clinical Oncology, Jensen et al have undertaken a study to estimate cancer population–based reference values for patient-reported outcome domains in the Patient-Reported Outcomes Measurement Information System (PROMIS). Study Details The study included...

solid tumors

Metastatic Uveal Melanoma Response to Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes

As reported by Chandran et al in The Lancet Oncology, a single-center study has shown that adoptive transfer of autologous tumor-infiltrating lymphocytes produces tumor responses in metastatic uveal melanoma. Study Details The study involved 21 consecutive patients treated at the Surgery Branch...

solid tumors

Avelumab in Refractory Metastatic Urothelial Carcinoma

The programmed cell death ligand 1 (PD-L1)–inhibitor avelumab (Bavencio) has shown activity in patients with refractory metastatic urothelial cancer, according to findings in a phase Ib study reported by Apolo et al in the Journal of Clinical Oncology. This patient cohort is part of the...

solid tumors
hematologic malignancies

AACR 2017: IDH-Mutant Cancers May Be More Amenable to Treatment With PARP Inhibitors Than IDH Inhibitors, According to Preclinical Findings

Tumors with mutations in the proteins isocitrate dehydrogenase-1 or -2 (IDH1/2) exhibited features similar to BRCA-mutant tumors and were more likely to respond better to PARP inhibitors than to IDH inhibitors, according to preclinical data presented by Sulkowski et al at the 2017 American...

solid tumors

AACR 2017: Cancer Type and Mutation Identity Influenced Response to Neratinib in a Basket Clinical Trial

In the phase II SUMMIT clinical trial, the likelihood that a patient’s cancer responded to the investigational pan-HER–targeted therapeutic neratinib was influenced by both the cancer type and the identity of the gene mutation present in the cancer, according to results presented by...

solid tumors

High-Throughput Genomics May Improve Outcomes in Difficult-to-Treat Cancers

A study investigating the hypothesis that testing a large number of genes across all cancer tumor types could improve outcomes for patients with difficult-to-treat cancers by using targeted therapies has found that progression-free survival was significantly higher in the those treated with...

solid tumors

First-in-Human Clinical Trial of ONC201 in Patients With Refractory Solid Tumors

A first-in-human clinical trial examining the investigational small-molecule drug ONC201 in patients with advanced solid tumors showed the oral agent to be well tolerated at the recommended phase II dose, according to Rutgers Cancer Institute of New Jersey investigators whose research also showed...

solid tumors

Pembrolizumab in PD-L1–Positive Malignant Pleural Mesothelioma

In an interim analysis of the phase IB KEYNOTE-028 trial reported in The Lancet Oncology, Alley et al found that pembrolizumab (Keytruda) treatment produced durable responses in patients with malignant pleural mesothelioma. Study Details The current report involves 25 patients with previously...

solid tumors

Cisplatin-Based Chemotherapy in Pediatric Extracranial Malignant Germ Cell Tumors

In a study reported in the Journal of Clinical Oncology, Shaikh et al, of the Children’s Oncology Group, found that event-free survival rates were not maintained with the use of reduced and compressed cisplatin-based regimens in children and adolescents with intermediate-risk extracranial...

solid tumors

Can Histone Deacetylase Inhibitors Reverse Resistance to Angiogenesis Inhibitors?

In a phase I study reported in the Journal of Clinical Oncology, Aggarwal et al found evidence that the histone deacetylase (HDAC) inhibitor abexinostat may act to reverse resistance to the vascular endothelial growth factor (VEGF) inhibitor pazopanib (Votrient) via epigenetic modulation of VEGF in ...

solid tumors

Shridar Ganesan, MD, PhD, on Mutation Burden and Immunotherapy

Shridar Ganesan, MD, PhD, of the Rutgers Cancer Institute of New Jersey, discusses mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.

solid tumors

Prasad S. Adusumilli, MD, on Solid Tumors: CAR T Cells and Immune Checkpoint Blockade

Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses a way to promote functional persistence of CAR T cells as an ideal strategy for solid tumor immunotherapy.

solid tumors

Stephen Gottschalk, MD, on CAR T Cells for Solid Tumors: What Are the Challenges?

Stephen Gottschalk, MD, of Baylor College of Medicine and Texas Children’s Hospital, discusses combining CAR T cells with checkpoint blockade or targeted treatments to improve their antitumor activity in solid tumors.

solid tumors

George J. Bosl, MD, and Karim Fizazi, MD, PhD, on Germ Cell Tumors and Treatment Intensification: Pros and Cons

George J. Bosl, MD, of Memorial Sloan Kettering Cancer Center, and Karim Fizazi, MD, PhD, of Gustave Roussy and the University of Paris Sud, offer the “pro” and “con” viewpoints for treatment intensification in patients with poor-prognosis germ cell tumors with unfavorable marker decline.

solid tumors

Lawrence H. Einhorn, MD, on Testicular Cancer: The Keynote Lecture

Lawrence H. Einhorn, MD, of the Indiana University Simon Cancer Center, summarizes his keynote lecture on the controversies in management of clinical stage I testicular cancer and the long-term consequences of platinum combination chemotherapy.

solid tumors
survivorship

Mohammad Abu Zaid, MD, on Testicular Cancer: Study Results on Metabolic Syndrome

Mohammad Abu Zaid, MD, of Indiana University Simon Cancer Center, discusses findings from a multicenter study of North American testicular cancer survivors, their prevalence of hypertension, risk factors for metabolic syndrome, and the need for screening and treatment (Abstract 102).

solid tumors

‘Collateral Lethality’ May Offer New Therapeutic Approach for Cancers of the Pancreas, Stomach, and Colon

Cancer cells often delete genes that normally suppress tumor formation. These deletions also may extend to neighboring genes, an event known as “collateral lethality,” which may create new options for development of therapies for several cancers. Scientists at The University of Texas MD ...

solid tumors

177Lu-Dotatate Improves Progression-Free Survival in Midgut Neuroendocrine Tumors

In a phase III trial (NETTER-1) reported in The New England Journal of Medicine, Strosberg et al found that the addition of the targeted radiotherapeutic agent lutetium-177 (177Lu)-Dotatate to octreotide long-acting repeatable (LAR) (Sandostatin LAR) significantly improved progression-free survival ...

solid tumors

Lower Locoregional Failure but Increased Toxicity With Addition of Cetuximab to Chemoradiotherapy for Anal Carcinoma

In a phase II trial (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group E3205) reported in the Journal of Clinical Oncology, Garg et al found that the addition of cetuximab (Erbitux) to definitive chemoradiotherapy appeared to reduce the...

solid tumors
issues in oncology

Genome-Based Model for Adjusting Radiotherapy Dose Shows Promise

In a retrospective cohort–based study reported in The Lancet Oncology, Scott et al found that individual patient genomic-adjusted radiation dose was associated with outcomes across different cancer types. Study Details In the study, gene-expression–based radiation-sensitivity index...

solid tumors

Successful Retreatment With Cisplatin-Based Therapy Reported in Men Relapsing After Adjuvant Carboplatin for Stage I Seminoma

In an analysis reported in the Journal of Clinical Oncology, Fischer et al found that men with clinical stage I seminoma who relapsed after adjuvant carboplatin could be successfully re-treated with cisplatin-based chemotherapy. Study Details The analysis included data from 185 patients who...

solid tumors

Activating NOTCH1 Mutations Identify Poor-Prognostic Subgroup With Adenoid Cystic Carcinoma

In a study reported in the Journal of Clinical Oncology, Ferrarotto et al found that the presence of activating NOTCH1 mutations defined a subgroup of patients with adenoid cystic carcinomas with an aggressive phenotype. Frequency of Mutations The study included genotyping of 102 adenoid cystic...

solid tumors

High-Dose Chemotherapy and Autologous PBSCT for Relapsed Metastatic Germ Cell Tumors

In a retrospective analysis reported in the Journal of Clinical Oncology, Adra et al found that good survival outcomes were achieved with the use of high-dose chemotherapy and peripheral blood stem cell transplantation (PBSCT) in second-, third-, or later-line treatment of patients with relapsed...

solid tumors

FDA Grants Priority Review to Pembrolizumab for New Indication in Microsatellite Instability–High Cancer

On November 28, the U.S. Food and Drug Administration (FDA) accepted for review the supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda) for the treatment of previously treated patients with advanced microsatellite instability–high (MSI-H) cancer. The FDA granted...

solid tumors
hematologic malignancies
skin cancer

SITC 2016: Phase I/II Data Combining Urelumab With Nivolumab Suggest Increased Antitumor Effect in Patients With Melanoma

Safety and efficacy data from a phase I/II study of urelumab in combination with nivolumab (Opdivo) in patients with hematologic and solid tumors, including biomarker analyses by level of programmed death ligand 1 (PD-L1) expression, was recently presented at the Society for Immunotherapy of Cancer ...

solid tumors

Factors in Clonal Evolution of Chemotherapy-Resistant Urothelial Carcinoma Identified

Faltas et al identified factors in the clonal evolution of chemotherapy-resistant urothelial carcinoma, according to a study reported in Nature Genetics. Findings included wide intrapatient mutational heterogeneity and enrichment for clonal mutations involving L1 cell–adhesion molecule...

solid tumors

Does Telotristat Ethyl Reduce the Frequency of Bowel Movements in Patients With Metastatic NETs and Carcinoid Syndrome?

In the phase III TELESTAR trial reported in the Journal of Clinical Oncology by Kulke et al, telotristat ethyl, a tryptophan hydroxylase inhibitor, significantly reduced the frequency of bowel movements in patients with metastatic neuroendocrine tumors and carcinoid syndrome. Telotristat ethyl...

solid tumors
hematologic malignancies

ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600–Mutated Tumors

Findings from a phase II trial of vemurafenib in previously treated patients with advanced disease and BRAF-mutated tumors indicate that the drug is effective in patients with diverse BRAF V600­–mutated tumors but not in patients with BRAF non-V600 mutations. After a mean treatment...

solid tumors
palliative care

Philippe Rochigneux, MD, on Solid Tumors: Use of Chemotherapy Near End of Life (French Language Version)

Philippe Rochigneux, MD, of the Paoli Calmettes Institute, Marseille Cancer Center, discusses in French his findings on the high rates of chemotherapy used at the end of life for metastatic solid cancer, especially in young patients treated in high-volume centers without a palliative care unit. (Abstract 1300O)

solid tumors
palliative care

Philippe Rochigneux, MD, on Solid Tumors: Use of Chemotherapy Near the End of Life

Philippe Rochigneux, MD, of the Paoli Calmettes Institute, Marseille Cancer Center, discusses his findings on the high rates of chemotherapy used at the end of life for metastatic solid cancer, especially in young patients treated in high-volume centers without a palliative care unit. (Abstract 1300O)

genomics/genetics
solid tumors

Janessa J. Laskin, MD, on Tumor Gene Expression and Advanced Cancers

Janessa J. Laskin, MD, of the British Columbia Cancer Agency, discusses the ways in which availability of tumor gene expression data facilitates clinical decision-making for patients with advanced cancers. (Abstract 1519O)

solid tumors

Modified Staging System for Pancreatic Neuroendocrine Tumors

As reported in the Journal of Clinical Oncology, Luo et al found that a modified staging classification based on the European Neuroendocrine Tumor Society (ENETS) and the American Joint Committee on Cancer (AJCC) staging classifications may improve distinction among risk groups in pancreatic...

solid tumors

Study Finds TP53 and MDM2 Alterations Linked to Cisplatin Resistance in Advanced Germ Cell Tumors

In a study reported in the Journal of Clinical Oncology, Bagrodia et al found that alterations in TP53 and MDM2 were associated with cisplatin resistance and poorer outcome in patients with advanced germ cell tumors. Actionable alterations were found in a high proportion of cases of cisplatin...

solid tumors
symptom management

Study Finds Pneumonitis Associated With Anti–PD-1/PD-L1 Antibody Treatment

In a two-institution experience reported in the Journal of Clinical Oncology, Naidoo et al identified the incidence of pneumonitis occurring in patients receiving anti–PD-1/PD-L1 (programmed cell death protein 1/ligand 1) monoclonal antibody as monotherapy or combined with anticytotoxic...

solid tumors
issues in oncology

CDC Finds Cancer Death Rates Among Children and Adolescents Declined by 20%, With Brain Cancer Topping Leukemia as Leading Cause of Death

New findings from the Centers for Disease Control and Prevention (CDC) show that the cancer death rate for children and adolescents aged 1 to 19 has been steadily declining since the mid-1970s and dropped by 20% from 1999 to 2014, the result of advances in therapy, especially for leukemia. During...

solid tumors

DNA Methylation Assay May Improve Diagnosis of Cancer of an Unknown Primary

As reported in The Lancet Oncology, Moran et al developed a classifier of cancer type based on microarray DNA methylation signatures (EPICUP assay), which has showed promise in diagnosing cancers of an unknown primary. Study Details The tumor type classifier was developed in a training set of...

solid tumors

Epigenetic Dysregulation of MicroRNA-34A Identified in TP53-Related Cancer Risk

In a genome-wide DNA-methylation analysis to identify genes implicated in Li-Fraumeni syndrome, Samuel et al found a significant association of loss-of-function <em>TP53</em> mutations with differential methylation at the locus encoding microRNA-34A (miR-34A). The study was reported in...

breast cancer
solid tumors

Breast Density and Risk Factors May Be Useful for Tailoring Breast Cancer Screening for Older Women

A collaborative modeling study evaluating outcomes for various screening intervals for women over the age of 50 based on breast density and risk for breast cancer has found that average-risk women with low breast density undergoing triennial screening and higher-risk women with high breast density...

solid tumors
gynecologic cancer

CA-125 Tests and CT Scans Still Routinely Used for Surveillance in Ovarian Cancer, Yet Benefit Remains Unproved

As reported by Esselen et al in JAMA Oncology, cancer antigen 125 (CA-125) tests and computed tomography (CT) scans for surveillance in women with ovarian cancer continue to be used routinely, although their benefit has not been proven and the practices have significant quality-of-life and economic ...

solid tumors
issues in oncology

Insurance Status Impacts Survival, According to Two New Studies

Men with testicular cancer who were uninsured or on Medicaid had a higher risk of death from what is normally a curable disease than insured patients, a new study found. The findings, published by Markt et al in Cancer, add to growing evidence that differences in health insurance status can affect...

solid tumors
head and neck cancer

Genetic Characteristics of Recurrent and Metastatic Head and Neck Cancers

Next-generation sequencing of recurrent or metastatic head and neck tumors at Memorial Sloan Kettering Cancer Center (MSK) has provided insight into the molecular characteristics of these tumors, which may aid in the implementation of precision treatment. Morris et al reported these findings in...

solid tumors
bladder cancer

High-Intensity Local Treatment May Improve Survival in Patients With Metastatic Urothelial Carcinoma of the Bladder

In a National Cancer Data Base analysis reported in the Journal of Clinical Oncology, Seisen et al found that high-intensity local treatment was associated with an overall survival benefit in patients with metastatic urothelial carcinoma of the bladder. Study Details The study included data from...

solid tumors

Vemurafenib Active in BRAF V600E–Positive Papillary Thyroid Cancer Refractory to Radioactive Iodine

In a phase II study reported in The Lancet Oncology, Brose et al found that vemurafenib (Zelboraf) had antitumor activity in patients with BRAF V600E–positive recurrent or metastatic papillary thyroid cancer refractory to radioactive iodine. Study Details In the study, 26 patients without...

solid tumors
issues in oncology

Increased Obesity Rates Reported in Adults With a History of Cancer

In a population-based study reported in the Journal of Clinical Oncology, Greenlee et al found that rates of obesity have increased more in patients with a history of cancer than in the general population. These rates were particularly high among survivors of colorectal and breast cancers and black ...

breast cancer
solid tumors

Neoadjuvant Veliparib/Carboplatin and Neratinib ‘Graduate’ From Adaptive Randomization I-SPY 2 Trial in Early Breast Cancer

As reported by Rugo et al and Park et al in The New England Journal of Medicine, the adaptive randomization phase II I-SPY 2 trial has shown that the addition of veliparib/carboplatin and the addition of neratinib to standard neoadjuvant therapy have met criteria predictive of success in a phase...

solid tumors
lung cancer

Ceritinib Shows Overall and Intracranial Activity in Advanced NSCLC Previously Treated With Crizotinib and Chemotherapy

Crinò et al found that ceritinib (Zykadia) was active overall and in central nervous system (CNS) metastases in patients with ALK-rearranged advanced non–small cell lung cancer (NSCLC) previously treated with crizotinib (Xalkori) and chemotherapy, according to the ASCEND-2 phase II...

breast cancer
solid tumors

Meta-analysis Indicates Similar Outcomes With Neoadjuvant Endocrine vs Chemotherapy in Estrogen Receptor–Positive Breast Cancer

In a meta-analysis reported in JAMA Oncology, Spring et al found that neoadjuvant endocrine therapy was associated with outcomes similar to those with chemotherapy in women with estrogen receptor–positive breast cancer. Similar Outcomes The analysis included 3,490 patients from 20...

Advertisement



Advertisement

click me